Navigation Links
Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
Date:4/26/2010

ompound miravirsen, the International Nonproprietary Name (INN) or generic name for the compound formerly known as SPC3649.

Miravirsen, the first microRNA-targeted drug to enter human clinical trials, is a specific inhibitor of miR-122, a liver-specific microRNA that the Hepatitis C virus requires for replication. Unlike Hepatitis C therapies that directly target the virus, miravirsen works by removing a "helper" molecule (miR-122) that the virus needs in order to make new copies. Miravirsen is being studied in a Phase 1 trial multiple-ascending dose study in healthy volunteers and a Phase 2 study in patients infected with Hepatitis C is expected to begin in the second half of 2010.

Santaris Pharma A/S also has a broad range of drug discovery and development programs with its partners: Shire plc (lead candidates against up to five targets for rare genetic disorders), Pfizer (lead candidates against up to ten targets), GlaxoSmithKline (options to drug candidates from up to four viral disease programs) and Enzon Pharmaceuticals (lead candidates against eight cancer targets successfully delivered).

About Locked Nucleic Acid (LNA) Drug Platform

The LNA Drug Platform utilizing Santaris Pharma A/S proprietary LNA chemistry provides the key to delivering on the promise of RNA-targeted therapies today by addressing these concerns and overcoming the limitations of earlier antisense and siRNA technologies to deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The unique combination of small size and very high affinity, which is only achievable with LNA-based drugs, allows this new class of drugs to potently and specifically inhibit RNA-targets in many different tissues without the need for complex delivery vehicles. LNA-based drugs are a promising new type of therapy that enables scientists to develo
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
5. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
6. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
7. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... South San Francisco, CA (PRWEB) April 16, 2015 ... it is scheduled to report first quarter results on ... Following the announcement, Cytokinetics’ senior management will host a ... operational and financial results and the company’s outlook for ... webcast and can be accessed from the homepage and ...
(Date:4/16/2015)... Proove Biosciences , Inc. is ... Contest for the 2015 BIO International Convention. Hosted ... International Convention will take place June 15-18 at the ... of BIO contest, industry leaders will be voting for ... conference. The community voting period began on April 14, ...
(Date:4/16/2015)... Morton Grove, IL (PRWEB) April 16, 2015 ... the American Association for Cancer Research (AACR) ... at the Pennsylvania Convention Center, starting Saturday, April 18, ... The AACR holds claim to title of the oldest ... several journals, provides fellowships and grants, and partners with ...
(Date:4/16/2015)... 2015 OncoTAb, Inc., ... Charlotte) spin-out company, announced today the appointment of ... as Chief Operating Officer (COO). Cooper brings to ... developing clinical diagnostic and biotechnology platforms in the ... Cooper’s extensive career transcends the field of medical ...
Breaking Biology Technology:Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3Regis Technologies Joins American Association for Cancer Research Annual Meeting 2OncoTAb Names Dr. David L. Cooper as COO 2
... Research Institute Introduce New Research Base and First ... DIEGO, Feb. 11 Leading global biopharmaceutical company, ... have opened a new and expanded, 38,000-square-foot facility ... be dedicated to further development of peptide research ...
... Chair the Board LA JOLLA, Calif., Feb. 11 ... the formation of a Medical Advisory Board to provide ... for the treatment of heart failure.The Medical Advisory Board ... and oversight of the planned CDP-1050 Phase 2 clinical ...
... Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, ... diseases caused by HIV-1 (Human Immunodeficiency Virus) and ... Ph.D., Chief Executive Officer and President, presented a ... & Investor Conference 2009, held at the Waldorf-Astoria ...
Cached Biology Technology:Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix 2Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix 3Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix 4Cordex Pharma Forms Heart Failure Medical Advisory Board 2Cordex Pharma Forms Heart Failure Medical Advisory Board 3Cordex Pharma Forms Heart Failure Medical Advisory Board 4Cordex Pharma Forms Heart Failure Medical Advisory Board 5GeoVax Update Provided at the BIO CEO & Investor Conference 2009 2GeoVax Update Provided at the BIO CEO & Investor Conference 2009 3GeoVax Update Provided at the BIO CEO & Investor Conference 2009 4GeoVax Update Provided at the BIO CEO & Investor Conference 2009 5
(Date:3/23/2015)... YORK , March 23, 2015   HOYOS ... property management company, today announced that the Company will ... for both enterprise and consumers at Connect:ID on March ... HOYOS Labs will highlight the IEEE Biometric ... TM ; and enterprise access control system. BOPS ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... Cleveland -- The use of padded headgear and gloves ... the head, according to newly published research from Cleveland ... Clinic,s Lutheran Hospital, the researchers replicated hook punches to ... pendulum. The impacts were measured under five padding configurations: ...
... This release is available in German . ... a draft version of the genome from a small fragment ... southern Siberia. The DNA sequences showed that this individual came ... become known as Denisovans. Together with their sister group the ...
... are you really eating when you,re eating chicken? Do different ... twins have similar fingerprints? How does sleep affect your memory? ... from 33 local schools will answer these and other intriguing ... the University of California, Riverside, Feb. 7-9. The fair will ...
Cached Biology News:Padded headgear, boxing gloves may offer some protection for fighters 2Entire genome of extinct human decoded from fossil 2Fair to bring future scientists and engineers to UC Riverside 2
Mouse monoclonal antibody to UGT2B10 - UDP glucuronosyltransferase 2 family, polypeptide B10...
Mouse monoclonal antibody raised against a partial recombinant WDR5. NCBI Entrez Gene ID = WDR5...
Mouse polyclonal antibody raised against a partial recombinant COASY. NCBI Entrez Gene ID = 80347...
... SM-2 adsorbents are macroporous polystyrene beads for ... surface area for adsorbing organics of molecular ... The beads are useful for the adsorption ... for example, the removal of detergents such ...
Biology Products: